Tentarix Biotherapeutics

Gilead Sciences (NASDAQ: GILD) has announced the initiation of three collaboration programs with US-based Tentarix Biotherapeutics, focusing on the discovery and development of conditional polyspecific antibodies for oncology and inflammatory diseases. The collaboration underscores Gilead’s commitment to advancing innovative treatments in these therapeutic areas. Financial Terms and Acquisition RightsUnder the…